Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus

Muhammad A Abdul-ghani, Luke Norton, Ralph A Defronzo

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

In addition to its central role in the development of microvascular complications, hyperglycemia plays an important role in the pathogenesis of type 2 diabetes mellitus (T2DM) by means of glucotoxicity. Thus, effective glycemic control not only reduces the incidence of microvascular complications but also corrects the metabolic abnormalities that contribute to the progression of the disease. Progressive β-cell failure and multiple side effects, including hypoglycemia and weight gain, associated with many current therapies present obstacles to the achievement of optimal and durable glycemic control in subjects with T2DM. Most recently, inhibitors of the renal sodium-glucose cotransporter have been developed to reduce the plasma glucose concentration by producing glucosuria. Because the mechanism of action of these oral antidiabetic agents is independent of β-cell function and tissue sensitivity to insulin, they improve glycemic control while avoiding hypoglycemia and promoting weight loss. In this review, we summarize the available data concerning the mechanism of action, efficacy, and safety of this novel antidiabetic class of therapeutic agents.

Original languageEnglish (US)
Pages (from-to)230-238
Number of pages9
JournalCurrent Diabetes Reports
Volume12
Issue number3
DOIs
StatePublished - Jun 2012

Fingerprint

Hypoglycemia
Hypoglycemic Agents
Type 2 Diabetes Mellitus
Sodium-Glucose Transport Proteins
Safety
Hyperglycemia
Weight Gain
Disease Progression
Insulin Resistance
Weight Loss
Kidney
Glucose
Incidence
Therapeutics

Keywords

  • Kidney
  • SGLT2 inhibition
  • Sodium-glucose cotransport
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. / Abdul-ghani, Muhammad A; Norton, Luke; Defronzo, Ralph A.

In: Current Diabetes Reports, Vol. 12, No. 3, 06.2012, p. 230-238.

Research output: Contribution to journalArticle

@article{a8affbcb957c478598b510bec4b7c20a,
title = "Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus",
abstract = "In addition to its central role in the development of microvascular complications, hyperglycemia plays an important role in the pathogenesis of type 2 diabetes mellitus (T2DM) by means of glucotoxicity. Thus, effective glycemic control not only reduces the incidence of microvascular complications but also corrects the metabolic abnormalities that contribute to the progression of the disease. Progressive β-cell failure and multiple side effects, including hypoglycemia and weight gain, associated with many current therapies present obstacles to the achievement of optimal and durable glycemic control in subjects with T2DM. Most recently, inhibitors of the renal sodium-glucose cotransporter have been developed to reduce the plasma glucose concentration by producing glucosuria. Because the mechanism of action of these oral antidiabetic agents is independent of β-cell function and tissue sensitivity to insulin, they improve glycemic control while avoiding hypoglycemia and promoting weight loss. In this review, we summarize the available data concerning the mechanism of action, efficacy, and safety of this novel antidiabetic class of therapeutic agents.",
keywords = "Kidney, SGLT2 inhibition, Sodium-glucose cotransport, Type 2 diabetes",
author = "Abdul-ghani, {Muhammad A} and Luke Norton and Defronzo, {Ralph A}",
year = "2012",
month = "6",
doi = "10.1007/s11892-012-0275-6",
language = "English (US)",
volume = "12",
pages = "230--238",
journal = "Current Diabetes Reports",
issn = "1534-4827",
publisher = "Current Medicine Group",
number = "3",

}

TY - JOUR

T1 - Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus

AU - Abdul-ghani, Muhammad A

AU - Norton, Luke

AU - Defronzo, Ralph A

PY - 2012/6

Y1 - 2012/6

N2 - In addition to its central role in the development of microvascular complications, hyperglycemia plays an important role in the pathogenesis of type 2 diabetes mellitus (T2DM) by means of glucotoxicity. Thus, effective glycemic control not only reduces the incidence of microvascular complications but also corrects the metabolic abnormalities that contribute to the progression of the disease. Progressive β-cell failure and multiple side effects, including hypoglycemia and weight gain, associated with many current therapies present obstacles to the achievement of optimal and durable glycemic control in subjects with T2DM. Most recently, inhibitors of the renal sodium-glucose cotransporter have been developed to reduce the plasma glucose concentration by producing glucosuria. Because the mechanism of action of these oral antidiabetic agents is independent of β-cell function and tissue sensitivity to insulin, they improve glycemic control while avoiding hypoglycemia and promoting weight loss. In this review, we summarize the available data concerning the mechanism of action, efficacy, and safety of this novel antidiabetic class of therapeutic agents.

AB - In addition to its central role in the development of microvascular complications, hyperglycemia plays an important role in the pathogenesis of type 2 diabetes mellitus (T2DM) by means of glucotoxicity. Thus, effective glycemic control not only reduces the incidence of microvascular complications but also corrects the metabolic abnormalities that contribute to the progression of the disease. Progressive β-cell failure and multiple side effects, including hypoglycemia and weight gain, associated with many current therapies present obstacles to the achievement of optimal and durable glycemic control in subjects with T2DM. Most recently, inhibitors of the renal sodium-glucose cotransporter have been developed to reduce the plasma glucose concentration by producing glucosuria. Because the mechanism of action of these oral antidiabetic agents is independent of β-cell function and tissue sensitivity to insulin, they improve glycemic control while avoiding hypoglycemia and promoting weight loss. In this review, we summarize the available data concerning the mechanism of action, efficacy, and safety of this novel antidiabetic class of therapeutic agents.

KW - Kidney

KW - SGLT2 inhibition

KW - Sodium-glucose cotransport

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84861098920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861098920&partnerID=8YFLogxK

U2 - 10.1007/s11892-012-0275-6

DO - 10.1007/s11892-012-0275-6

M3 - Article

VL - 12

SP - 230

EP - 238

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

IS - 3

ER -